xuanxuan
Lv33
368 积分
2021-04-15 加入
-
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2天前
已完结
-
Breast cancer, screening and diagnostic tools: All you need to know
2天前
已完结
-
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
9天前
已完结
-
Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer
9天前
已完结
-
Establishment of RWS guidance reflecting contributions of China to regulatory science
22天前
已完结
-
Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma
30天前
已完结
-
Operationalizing multidisciplinary liver tumor boards for hepatocellular carcinoma
30天前
已关闭
-
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
1个月前
已完结
-
CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis
1个月前
已完结
-
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4
1个月前
已完结